Genmab — Juni 2019

[E_L]

i haven't seen it before, no

[E_L]

next question is; will it work in solids

[bibob]

Lets hope so.

[Bulder]

There is not that much cd38 on solid tumors. The reason why dara was thought to be effective in solids was that it could strengthen the efficacy of a PD(L)-1 inhibitor by blocking cd38. I don't know if a boosted cd38 would be of any help here. But I think we need Sukkeralf on this subject.

[Sukkeralf]

If I remember correctly Jans first thoughts of new INDs for 2019 was 3-5 and recently it was 3 (and we know them all) but maybe HexaCD38 could have been close so I hope it will be a 2020 IND

[lahn1]

@09:28 yes I see that now. It stille feels early to do this deal, hence the "pure milestone
payement"

[Sukkeralf]

But the deal need to be in place for Genmab to do the costly preclinical work

[lahn1]

yes nice to have a buyer on hand, maybe not as bad a deal as it seemed at first glance

[nohope]

I´ll welcome almost any kind of deals, also, this deal, but it does seem rather far away from what Jan has been talking about. This is a techdeal with a product, this should have been paid upfront and/or on 50/50 basis. But any hole in the no-deal-wall is welcome to me.

[E_L]

I am actually very excited about this deal- Dara is the backbone of this company and Genmab is looking to strengthen and extend that backbone. Extremely important and a sign of mature management with a long term view imo. I really like Sukkeralf's term 'life cycle management' in this respect.

[E_L]

@nohope 09:21 is my answer to that.

[nohope]

Well, you could also say, this emphasasi that GEN is a one-trick pony - Darapony.

[E_L]

even if that would be right; i would rather have a strong pony that lives longer

[nohope]

Ok, I see. Too bad, but still better than the Theresa May scenario

[nohope]

Ponies forever

[Solsen]

To me the agreement is still like Genmab asking Janssens for a deal - not a move from Janssens.

[Solsen]

Perhaps its foresight ?

[Sukkeralf]

when sc dosing of CD38 it should be secured until 2033-35...........a with all the alternatives Janssen is doing right now I agree with Solsen that Genmab has pushed this foreward and Janssen at last agree to "show us what it can do"

[Sukkeralf]

But a nice deal to get in place before a DR5/DR5 deal and to get HexaBody and perhaps HexElect in the spotlight

[troldmanden]

mindes ikke lige at have set en sådan struktureret deal før. Uden noget i upfront